Pluri (NASDAQ:PLUR – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.11, FiscalAI reports. The business had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.66 million.
Pluri Price Performance
NASDAQ:PLUR traded down $0.11 on Thursday, reaching $3.40. The stock had a trading volume of 10,666 shares, compared to its average volume of 8,451. The company has a market cap of $36.62 million, a price-to-earnings ratio of -0.69 and a beta of 0.75. The firm’s fifty day moving average is $3.36 and its two-hundred day moving average is $3.42. Pluri has a 12-month low of $2.82 and a 12-month high of $5.96.
Analyst Ratings Changes
Separately, Weiss Ratings upgraded shares of Pluri from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $12.00.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Pluri stock. Jane Street Group LLC acquired a new stake in shares of Pluri Inc. (NASDAQ:PLUR – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned about 0.14% of Pluri at the end of the most recent reporting period. 16.59% of the stock is owned by institutional investors and hedge funds.
About Pluri
Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.
Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.
Featured Articles
- Five stocks we like better than Pluri
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for Pluri Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluri and related companies with MarketBeat.com's FREE daily email newsletter.
